In September, 2003, a team from St. Vincent’s Hospital (Melbourne, Australia) published a piece in Journal of Clinical Neuroscience titled “The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months.” That article, by F.J. Vajda et
Justinian Lane
Justinian Lane is a legal publisher specializing in asbestos and mesothelioma claims, operated as a division of Justinian C. Lane, Esq. – PLLC. The organization provides detailed information on asbestos litigation, related diseases, and compensation claims, including guidance on filing asbestos claims and understanding asbestos trusts. Their content covers various sources of asbestos exposure, symptoms, treatments, and legal history. The publisher also addresses related legal areas such as workers' compensation, veterans disability claims, and maritime claims. Justinian Lane maintains a database of asbestos trusts and offers resources for affected individuals seeking legal assistance and compensation.
Latest from Justinian Lane - Page 7
1999 – Researchers find Depacon, Depakene, and Depakote linked to major congenital abnormalities
Published in a 1999 edition of Annals of Neurology, an article by E.B. Samrén et al. titled “Antiepileptic drug regimens and major congenital abnormalities in the offspring.” provides important insight into the risks of prenatal exposure to antiepileptic…
Prenatal exposure to Depacon, Depakene, Depakote linked to lower intelligence in children
Over the past ten years or so, dozens of studies have been published linking prenatal exposure to the antiepileptic drugs Depacon, Depakene, and Depakote (Abbott Laboratories, Inc.) with birth defects. Here, I will summarize one such study,…
1997 – Team finds Depacon / Depakene / Depakote to lift malformation risk up to 700%
Back in 1997, a team of Dutch medical researchers led by E.B. Samrén published an article titled “Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with…
Birth defects risk 2-3 times higher with Depacon exposure
From a team of Swedish researchers, an article appearing in the November, 2009 edition of Neurologic Clinics titled “Teratogenic effects of antiepileptic medications.” provides important insight into the connection between prenatal exposure to epilepsy drugs Depacon, Depakene, and…
2011 – Depakote only drug to lift birth defect risk in polytherapy
A study titled “Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.” by L.B. Holmes and a team from MassGeneral Hospital for Children (Boston, MA) published in the October, 2011 edition of Archives of Neurology further…
New England Journal of Medicine: Depacon Causes Defects, Decreased Cognitive Function
Titled “Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.”, an article by K.J. Meador and a team from Emory University published in the April, 2009 edition of New England Journal of Medicine provides…
Depacon, Depakote, and Depakene carry risk for birth defects at 6.7%
In February of this year, E. Campbell and a team from Royal Victoria Hospital (Belfast, UK) published a piece in Journal of Neurology, Neurosurgery, and Psychiatry titled “Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the…
Reduced cognitive ability linked to prenatal Depacon / Depakene / Depakote exposure
In March, 2013, a medical research team led by K.J. Meador published an article in Lancet Neurology titled “Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.”. This team from…
Depakote linked to birth defects, poor neonatal development
In recent years, a number of independent medical research teams have determined that prenatal exposure to antiepileptic drugs branded Depacon, Depakene, and Depakote is linked to increased risk for birth defects. Here, I will discuss research from one such team…